{
    "2021-10-08": [
        [
            {
                "time": "",
                "original_text": "贝达药业（300558.SZ）：拟斥不超8000万美元认购Xcovery新发行F轮优先股 持股比例升至69.53%",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "Xcovery",
                        "F轮优先股",
                        "8000万美元",
                        "持股比例",
                        "69.53%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业（300558.SZ）拟认购Xcovery新发行F轮优先股 推进恩沙替尼项目",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "Xcovery",
                        "F轮优先股",
                        "恩沙替尼"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：不超8000万美元认购Xcovery新发行F轮优先股",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "Xcovery",
                        "F轮优先股",
                        "8000万美元"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "创新药周报：2021年9月第五周",
                "features": {
                    "keywords": [
                        "创新药",
                        "周报",
                        "2021年9月第五周"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "解密益方生物等创新药授权合作模式 挖掘医药“潜力股” | 新闻稿",
                "features": {
                    "keywords": [
                        "益方生物",
                        "创新药",
                        "授权合作",
                        "潜力股"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "兴证医药2021年10月投资月报：新冠药物新冠疫苗专题分析",
                "features": {
                    "keywords": [
                        "兴证医药",
                        "2021年10月",
                        "投资月报",
                        "新冠药物",
                        "新冠疫苗"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}